GlaxoSmithKline: Phase 2 study in Pulmonary Disease, Chronic Obstructive (279 participants)
GlaxoSmithKline: Phase 2 study in Pulmonary Disease, Chronic Obstructive (279 participants). Its enrollment of 279 is above the median of 80 (82nd percentile). Dated 1 day ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 279 · 82th percentile of 9,177 ClinicalTrialStartPulse records · 3.5x the median
Free preview: all 13 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
| NCT ID | NCT07915791 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention types | drug |
| Target enrollment | 279 |
| Posted | 2026-11-04 |
| Planned start | 2026-11-09 |
| Event | Newly registered study |
| Event date | 2026-11-04 |
| enrollment percentile | 82th of 9,177 (median 80, 3.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch GlaxoSmithKline
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock GlaxoSmithKline + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-04
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: GlaxoSmithKline and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- GlaxoSmithKline's enrollment: 82nd percentile of 9,177 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- 279 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for GlaxoSmithKline?
GlaxoSmithKline registered a Phase 2 study (NCT07915791) in Pulmonary Disease, Chronic Obstructive targeting 279 participants, posted 2026-11-04.
How does GlaxoSmithKline compare to other ClinicalTrialStartPulse records?
Its enrollment of 279 sits in the upper half (82th percentile) of 9,177 records; the median is 80. It is fresh: dated 1 day ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
GlaxoSmithKline vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| GlaxoSmithKline | NONUS | 279 | 82nd | 2026-11-04 |
| Genfleet Therapeutics (Shanghai) Inc. | NONUS | 150 | 71st | 2026-11-04 |
| Enlivex Therapeutics Ltd. | NONUS | 134 | 67th | 2026-11-04 |
| Tortugas Neuroscience, Inc. | NONUS | 100 | 60th | 2026-11-04 |
Related records
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor GlaxoSmithKline and peer phase 2 records
Get new ClinicalTrialStartPulse records like GlaxoSmithKline by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.